| INTRODUCTION
The prevalence of type 2 diabetes has risen significantly in our society, even in children and adolescents. 1 Type 2 diabetes in youth leads to increased risk for cardiovascular disease (CVD) in adulthood. 2 An important contributor to elevated CVD risk in type 2 diabetes is dyslipidemia involving abnormalities in all lipoproteins. 3, 4 Typically, patients with type 2 diabetes show increased levels of small dense low-density lipoprotein (LDL) cholesterol, 5 decreased levels of highdensity lipoprotein (HDL) cholesterol, and increased levels of triglycerides. 6 Numerous large-scale trials have shown that intensive LDL-lowering therapy in patients with type 2 diabetes results in a significant reduction in CVD risk and improved outcomes. 7 One of the key regulators of circulating LDL cholesterol is proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 promotes the degradation of the LDL receptor (LDLR), resulting in reduced LDL clearance. [8] [9] [10] Thus, gain-of-function PCSK9 genetic variants lead to higher levels of LDL cholesterol and increased risk of CVD, whereas loss-of-function PCSK9 mutations are associated with reductions in both LDL cholesterol and risk of CVD. 11, 12 As a result, PCSK9 has become a novel target for lipid-lowering therapy, and medications that antagonize PCSK9 are now available for clinical use. 13 The effect of diabetes on PCSK9 is unclear. Circulating PCSK9 was found to be higher in individuals with diabetes compared with those without diabetes in some adult studies, 14, 15 but not in others. [16] [17] [18] Moreover, the effect of diabetes on PCSK9 levels in young adults has thus far not been studied, despite the fact that adolescents and young adults with obesity and type 2 diabetes are also at increased risk for dyslipidemia. 19 Indeed, the earlier onset of type 2 diabetes in this population implies a longer lifetime burden of disease and potential for earlier development of complications. 20, 21 The purpose of this study was to compare PCSK9 in youth with type 2 diabetes to their lean and obese controls.
| METHODS

| Participants
Extensive details of this cohort have previously been published. 
| Data collection
All participants completed an in-person study visit, during which demographics, medication history, anthropometrics, and a fasting (>10 hours) blood sample were obtained. Height and weight were obtained twice and averaged as previously described. 22 For this study, 286 participants were randomly selected from the lean, obese, and type 2 diabetes groups, and were matched for age and sex between each group using the frequency matching method.
Selected study subjects ranged in age from 15 to 26 years. Subjects who reported taking lipid-lowering medications, such as statins, at the time of the study were excluded from the analyses as these medications have been shown to increase PCSK9 levels. [26] [27] [28] Serum PCSK9 levels were determined in duplicate using a commercially available quantitative sandwich enzyme immunoassay ELISA (Cat.
No. Circulex CY-8079; CycLex Co., Ltd., Nagano, Japan), according to manufacturer's instructions. The intra-assay coefficient of variability (CV) was 8.2%. The interassay CV was 9.7%.
| Statistical analysis
All analyses were performed with Statistical Analyses Software (SAS, version 9.3). Data are presented as mean and standard deviation, frequency and percent, or median and interquartile range. Variancestabilizing measures to transform non-normal values were performed as appropriate for parametric analyses. χ 2 analyses were performed to determine group differences for categorical variables. Independent t tests, 1-way ANOVA, and ANCOVA were performed to test for mean differences between the groups. Bivariate correlations were calculated between PCSK9 levels and potential covariates. Multivariate linear regression models were constructed using race, sex, and group to elucidate the independent determinants of PCSK9. Group was chosen over BMI because it was a key factor in the study design, and the independent effects of BMI and group on PCSK9 were difficult to discern. Interactions between group and the other potential independent determinants of PCSK9 were also evaluated. P-value <.05 was considered significant for all analyses.
3 | RESULTS Table 1 lists the demographic, anthropometric, and laboratory data for all participants, stratified by study group. By design, there were no significant age or sex differences between the 3 groups. As expected, fasting plasma glucose and insulin levels differed significantly between all 3 groups (P < .01). Plasma lipids varied among the groups, with total cholesterol, LDL, and non-HDL cholesterol increasing from lean to obese to type 2 diabetes (P < .01). In addition, plasma CRP levels were higher in the subjects with obesity and diabetes, compared with lean controls (P < .01).
The PCSK9 measurements by group and by sex are presented in Figure 1 . Overall, PCSK9 concentrations differed significantly between the lean, obese and type 2 diabetes groups ( Figure 1A) . A similar relationship was present in females Figure 1B ). In males, PCSK9 levels were lower than in females (P = .03; Figure 1C ), and PCSK9 levels did not differ between lean, obese, and type 2 males ( Figure 1B) . Although race differed significantly between the groups (Table 1; Table S1 ), it did not have an independent effect on PCSK9 levels, and the relationships between PCSK9 and group, and PCSK9 and sex, remained significant after controlling for race (data not shown). The racial composition of study subjects by sex and group is shown in Table S1 . Table 2 shows the bivariate correlations between PCSK9 levels and other clinical variables by sex. Overall, PCSK9 levels significantly correlated with BMI (P < .001), systolic blood pressure (P = .002), fasting glucose (P = .003), fasting insulin (P < .001), and CRP (P = .02) in females, but not in males. Correlations between PCSK9 and total cholesterol, LDL, and non-HDL were observed in both males and females (P ≤ .008).
| DISCUSSION
We find that PCSK9 levels are increased in young women with obesity/type 2 diabetes and associated with metabolic dysfunction.
In contrast, PCSK9 levels in young men are lower than in young women, and are not associated with metabolic dysfunction.
Several studies in adults have also shown type 2 diabetes to be associated with increased levels of PCSK9. 14 Abbreviations: BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, lowdensity lipoprotein; PCSK9, Proprotein convertase subtilisin/kexin type 9.
a Values are mean (SD).
b Values are median (interquartile range).
c Indicates non-normally distributed data; Kruskal-Wallis test was used for comparisons between groups.
d Indicates data that was log transformed to achieve normality; 1-way ANOVA was used for comparisons between groups.
e Comparisons between groups using Fisher's exact test.
were performed in largely or exclusively Caucasian 18 or Asian 33 populations. This raises the possibility that the effects of diabetes on PCSK9 may be influenced by the racial composition of the population being studied.
Prior studies have also shown PCSK9 levels to be elevated in females vs males, in both adults and children. 14, 32, 34, 35 Furthermore, some of these studies found associations between PCSK9 and BMI that were either stronger or only present in females. Interestingly, mice also appear to manifest a sex-dependent association between PCSK9 and body weight, although in this case, the association may be more prominent in males: leptin treatment of obese mice produced similar weight loss in males and females, which was associated with a 90% decrease in plasma PCSK9 in males, but no change in plasma PCSK9 in females. 36 Taken together, these data suggest that the effects of obesity on PCSK9 could be modified by sex.
The mechanisms underlying the sex differences observed in PCSK9 levels remain unclear; however, most of the data to date suggest that estrogen suppresses PCSK9. Although estrogen replacement does not significantly alter plasma PCSK9 in postmenopausal females, 37, 38 high-dose estradiol treatment suppresses hepatic PCSK9 expression in rats. 39 Moreover, plasma PCSK9 is higher in postmenopausal compared with premenopausal women, 35 and is inversely correlated with endogenous estrogen levels in healthy women. 40 In addition, studies in cells and mice have raised the possibility that estrogen may alter PCSK9 activity. First, estrogen treatment of cultured human hepatocarcinoma cells increases PCSK9 phosphorylation and impairs the ability of PCSK9 to promote LDLR degradation. 41 Second, PCSK9 appears to interfere with the accumulation of the LDL receptor at the plasma membrane only in the absence of estrogen. 42 Interestingly, we found that females with obesity and type 2 diabetes had the highest levels of PCSK9, suggesting that these metabolic states could potentially impact the relationship between estrogen and PCSK9.
One limitation of our study is that we did not assess pubertal status in all the subjects. This is potentially important because sexdependent changes in PCSK9 have been observed during the peripubertal years; in boys, PCSK9 decreased from ages 9 to 16 years, whereas in girls, PCSK9 levels trended upwards. 32 However, most of the males in our study were 15 years of age or older, and almost all of the females were postmenarcheal by report, suggesting that the majority of our patients were in the later stages of puberty or were postpubertal. Thus, it is unlikely that differences in pubertal status confounded our results.
In summary, in a young adult population, we show that PCSK9 is increased in subjects with obesity and type 2 diabetes, but that this increase is limited to females. In the absence of diabetes, women, relative to men, are protected against CVD. 43, 44 In contrast, the rate of CVD in diabetic females is equivalent to the rate of CVD in non-diabetic males. 45 Given recent findings that circulating PCSK9 may predict future cardiovascular events, 46 it is possible that PCSK9 mediates the increased risk of CVD observed in females with diabetes. Thus, therapies targeting PCSK9 may eventually prove to be of particular benefit to young females with obesity and type 2 diabetes.
